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Background: High frequencies of the BRAF V600E mutation have been reported in pleomorphic
xanthoastrocytoma (PXA). Recently, a BRAF V600E mutation-specific antibody has been developed and validated.
We evaluated the immunohistochemical (IHC) detection of BRAF V600E mutation in PXA by comparing to gold
standard molecular analysis and investigating the interobserver variability of the IHC scoring. We performed BRAF
V600E IHC in 46 cases, of which 37 (80%) cases had sufficient tumor tissue for molecular analysis. IHC detection was
performed using monoclonal mouse antibody VE1 (Spring Bioscience). IHC slides were scored independently by
four reviewers blind to molecular data, including a primary (gold standard) and three additional reviewers. BRAF
V600E mutation status was assessed by allele-specific polymerase chain reaction (PCR) with fragment analysis.
Results: All 46 cases showed interpretable BRAF V600E IHC results: 27 (59%) were positive (strong cytoplasmic
staining), 19 (41%) were negative (6 of these cases with focal/diffuse weak cytoplasmic staining, interpreted as
nonspecific by the primary reviewer). By molecular analysis, all 37 cases that could be tested had evaluable results:
22 (59%) cases were positive for BRAF V600E mutation and were scored as “IHC-positive”, and 15 (41%) were
negative (including 11 cases scored as “IHC-negative” and 4 cases scored as negative with minimal nonspecific
staining). IHC detection of BRAF V600E mutant protein was congruent in all 37 cases that were successfully
evaluated by molecular testing (sensitivity and specificity of 100%). Agreement for IHC scoring among the 4
reviewers was almost perfect (kappa 0.92) when cases were scored as “positive/negative” and substantial
(kappa 0.78) when minimal nonspecific staining was taken into account.
Conclusions: We conclude that detection of BRAF V600E mutation by immunohistochemistry is highly sensitive
and specific. BRAF V600E IHC interpretation is usually straightforward, but awareness of possible nonspecific staining
is necessary and training is recommended. It is a practical rapid method that may avoid the need of labor-intensive
molecular testing and may be most valuable in small biopsies unsuitable for molecular analysis.
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BRAF, a member of the RAF family including ARAF,
BRAF and RAF1, is a serine/threonine protein kinase
encoded by BRAF gene on chromosome 7q34 that activates
the MAP kinase/ERK-signaling pathway mediating cellular
responses to growth signals. It is the family member that is* Correspondence: giannini.caterina@mayo.edu
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reproduction in any medium, provided the ormost easily activated by RAS, and the one with highest
kinase activity [1-3]. Frequent somatic mutational activation
of BRAF has been observed in human cancers, including
melanomas, gliomas, colorectal cancers, lung cancers
and others [4]. Among primary central nervous system
(CNS) neoplasms [5-9], activation of the MAP kinase/
ERK-signaling pathway appears to play an important
role in the pathogenesis of a subset of glial/glioneuronal
tumors, in particular, pilocytic astrocytoma (PA) [8-13],
PXA [14], ganglioglioma (GG) [9,15], and dysembryoplastic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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primarily results from tandem duplications at 7q34 with
subsequent fusion between the 5’ end of a gene of unknown
function, KIAA1549, and the 3’ end of BRAF; while in PXA,
GG and DNET, constitutive BRAF activation results from
heterozygous missense mutation at codon 600 (V600E).
BRAF V600E mutation is characterized by exchange of T
to A at base position c.1799 (c. 1799 T >A), which results
in substitution of glutamic acid by valine at residue 600
(p. Val600Glut). Less frequent activating BRAF mutations
(e.g. V600K, V600D, V600M) have been observed in
malignant melanoma [17-20] and other non-CNS tumors
[4,21] but only rarely have been identified in primary CNS
tumors [6].
The highest frequencies of BRAF V600E mutation in
primary CNS neoplasms have been reported in PXA
(up to 60-65%) [8,9,14,22], a WHO grade II tumor [23],
with 30% recurrence and 80% overall survival rates at five
years following primary resection. Histologically, PXA is
characterized by marked cellular pleomorphism, nuclear
atypia, and a variable number of bizarre, multinucleate
giant cells (“classic PXA”), and occasionally shows increased
mitotic activity and/or necrosis (“PXA with anaplastic
features”) [23,24]. The main morphological differential
diagnosis of PXA includes other pleomorphic and
often more aggressive tumors such as glioblastoma
(GBM)/giant cell or epithelioid GBM, a World Health
Organization (WHO) grade IV tumor [23]. Such critical
clinical distinction with important prognostic and clinical
implications may be morphologically challenging. Of note,
BRAF V600E mutation has been found in low frequency
among GBM/giant cell GBM (approximately 5-10%)
[5,7,14], but in up to 54% among epithelioid GBM [25].
Therefore, BRAF V600E mutation assessment may be a
potentially useful marker in the differential diagnosis of
GBM/giant cell GBM vs. “PXA with anaplastic features”
and in identifying BRAF V600E mutant astrocytic tumors
suitable for targeted therapy.
Recently, a BRAF V600E mutation-specific monoclonal
antibody has been developed [26] and validated as a reliable
test among tumors that frequently harbor the BRAF V600E
mutation, including primary and metastatic melanoma
[18,20,27,28], papillary thyroid carcinoma [29,30], hairy cell
leukemia [31], ovarian serous borderline tumors [32],
primary lung adenocarcinomas [33], as well as in a large
series of brain metastases and corresponding non-CNS
primary tumors [34].
Herein, we evaluated the IHC detection of BRAF V600E
mutant protein in PXA by comparing to BRAF V600E mu-
tation detection by molecular analysis, and investigated the
interobserver variability of the IHC scoring. Detection of
BRAF V600E mutation in PXA by immunohistochemistry
was highly sensitive and specific, and showed a substantial/
almost perfect interobserver agreement.Results
BRAF V600E mutation immunohistochemical and
molecular analyses
All 46 (100%) cases with available tissue were evaluable by
immunohistochemistry for BRAF V600E mutant protein.
Cases were scored as positive if non-ambiguous tumor cell
cytoplasmic staining was identified (“IHC-positive”). BRAF
V600E immunoreactivity in most cases was characterized
by intense cytoplasmic stain, with a somewhat granular
appearance, likely due to the visualization/amplification
set used and with variable distribution. In some cases, all
tumor cells stained; while in others, the stain was patchy
in the tissue sections. Isolated tumor cells infiltrating
parenchyma were also visualized by the immunostain.
According to the primary reviewer, 27 (59%) cases were
“IHC-positive,” and 19 (41%) cases were “IHC-negative,”
including 6 cases “IHC-negative/nonspecific.” Examples of
immunostaining pattern are shown in Figures 1 and 2.
Immunostaining varied in intensity from strong (Figure 1A)
to weak (Figure 1B), as well as in distribution, with cases
showing isolated infiltrating tumor cells (Figure 1C).
Among cases considered negative (“IHC-negative”),
although the majority of cases did not have any degree of
immunostaining (Figure 2A), a few showed very focal
and/or weak tumor cell cytoplasmic staining as shown in
Figures 2B and 2C. This focal/weak immunostaining was
interpreted as nonspecific (“IHC-negative/nonspecific”).
Among the 37 (of 46, 80%) cases with sufficient tumor
tissue for molecular analysis: 22 (of 37, 59%) were positive
for BRAF V600E mutation, including 16 classic PXA and
6 PXA with anaplastic features, and 15 (41%) cases were
negative for BRAF V600E mutation, including 7 classic
PXA and 8 PXA with anaplastic features. All 22 cases
positive for BRAF V600E mutation (Figure 1D; Additional
file 1: Figure S1 for complete electropherogram panel) had
been scored as “IHC-positive.” Of the 15 cases negative
for BRAF V600E mutation (Figure 2D; Additional file 2:
Figure S2 for complete electropherogram panel), 11 had
been scored as “IHC-negative” and 4 as “IHC-negative/
nonspecific” cases (Table 1). Therefore, there was complete
agreement between BRAF V600E mutation molecular
analysis and IHC detection of BRAF V600E mutant protein
in all 37 cases, with sensitivity of 100% (confidence interval
85.1-100) and specificity of 100% (79.6-100) according to
the primary reviewer.
Interobserver variability of BRAF V600E
immunohistochemical analysis
Most (26) cases scored as “IHC-positive” by the primary
reviewer were also interpreted as “IHC-positive” by the
other three reviewers (Figure 3: Table 2 ), with the ex-
ception of one “IHC negative/nonspecific” interpretation
by a single reviewer. However, reviewers three and four
also scored as positive one additional case among those
Figure 1 BRAF V600E IHC positive PXA cases molecularly confirmed as BRAF V600E mutant tumors: case 17- strong granular cytoplasmic
immunostaining of a characteristic pleomorphic multinucleated giant tumor cell (A), case 3- weak granular cytoplasmic immunostaining of
pleomorphic and spindle tumor cells (B), case 10- strong granular cytoplasmic immunostaining of a cluster of isolated tumor cells (C),
400X; and case 14- mutant BRAF V600E peak in addition to the wild-type BRAF peak, consistent with presence of BRAF V600E mutation (D).
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reviewer (Figure 3: Table 2 ). All 13 cases scored as
“IHC-negative” by the primary reviewer were also scored
as “IHC-negative” by reviewers two and three, while
reviewer four scored two of them as “IHC-negative/
nonspecific.” The results of the review of the remainingFigure 2 BRAF V600E IHC negative & “negative/non-specific” PXA cas
case 38- BRAF V600E IHC negative case characterized by complete lac
“negative/non-specific” case showing focal weak granular cytoplasmi
“negative/non-specific” case with focal weak granular cytoplasmic im
immunostaining precipitate background (C); 400X; and case 20- BRAF
with the absence of BRAF V600E mutation and in keeping with the nesix cases interpreted as “IHC-negative/nonspecific” by
the primary reviewer as well as the results of the BRAF
V600E mutation molecular analysis are detailed in
Figure 3: Table 2. In summary: two cases were scored
as “IHC-negative” by the other three observers; two
cases were also scored as “IHC-negative/nonspecific”es molecularly confirmed as BRAF V600E non-mutant tumors:
k of tumor cell immunostaining (A), case 20- BRAF V600E IHC
c immunostaining of tumor cells (B), case 47- BRAF V600E IHC
munostaining of tumor cells in addition to small extracellular
wild-type peak without mutant BRAF V600E peak, consistent
gative BRAFV600E IHC (D).
Table 1 BRAF V600E mutation and BRAF V600E IHC
(Primary reviewer) comparison (n = 37)
BRAF V600E Mutation BRAF V600E IHC
Positive Negative Negative/Nonspecific
Mutant 22 0 0
Non-mutant 0 11 4
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observers; one case was scored as “IHC-negative” by two
observers and as “IHC-positive” by one observer; one case
was also scored as “IHC-negative/nonspecific” by one
observer and as “IHC-positive” by the other two observers.
Agreement for IHC scoring was almost perfect
(kappa 0.92) when cases were scored as “positive/negative”
(“IHC-positive” vs. “IHC-negative”) and substantial
(kappa 0.78) when “negative/nonspecific” staining was
taken into account (“IHC-positive” vs. “IHC-negative”
vs. “IHC-negative-nonspecific”).
Discussion
In keeping with the majority of previous studies that also
evaluated the immunohistochemical detection of the BRAF
V600E mutation in comparison to gold standard molecular
testing in a variety of tumor types [16,18,20,26-34], we
concluded that immunohistochemistry is an accurate
detection method for the BRAF V600E mutation in
PXA. In our study, IHC results were comparable to the
gold standard molecular testing for identification of
BRAF V600E mutation and resulted in high sensitivity
and specificity. In contrast to the labor-intensive de-
tection of BRAF V600E mutation by molecular test-
ing, identification of BRAF V600E mutant protein by
immunohistochemistry is a rapid method that may beFigure 3: Table 2 BRAF V600E IHC Interobserver variability (n = 46). Nquickly implemented in diagnostic pathology practice
since it is a widespread technique available in most
academic centers as well as in non-academic pathology
practices. However, validation of the BRAF V600E muta-
tion IHC specificity by comparative molecular analysis
should be performed for each tumor entity before routine
diagnostic implementation, since it has been recently
reported that in pituitary adenomas, the BRAF V600E
mutation-specific VE1 immunostaining is not associated
with presence of BRAF V600E mutation [35].
In surgical neuropathology, BRAF V600E mutation-
specific immunohistochemistry has a potential clinically
relevant role. IHC detection of BRAF V600E mutant
protein is an accurate and reliable alternative method
that may be diagnostically useful when dealing with
morphologically challenging pleomorphic astrocytic tumors
in which the differential diagnoses include PXA and GBM/
giant cell GBM. In addition, BRAF V600E mutation has
also been identified to a lesser extent in epithelioid
GBM[25], ganglioglioma and pilocytic astrocytoma,
predominantly in extra-cerebellar location [9], expanding
the diagnostic repertoire use of BRAF V600E mutation-
specific IHC testing among primary CNS tumors and
potentially the identification of tumors suitable for BRAF
V600E mutation-targeted therapy.
Of note, low tumor cell content may prevent identifica-
tion of the BRAF V600E mutation by molecular analysis
and result in false-negative results, but this limitation has
been shown to be overcome by the use of BRAF V600E
monoclonal antibody [18,29,30,32,34]. Thus, small biopsies
that would be deemed unsuitable for molecular testing may
be successfully evaluated by immunohistochemistry. This is
particularly important in surgical neuropathology, in which
biopsy samples of small size and/or with low tumor celleg/NS = negative/non specific. ND = not done.
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analysis allows identification of tumor cells at the single cell
level, which would not only aid in the diagnosis of biopsies
with very low tumor cell content but would also allow
localization of the mutation at a cellular type level, as re-
cently highlighted by the demonstration of neuronal tumor
cells as the predominant tumor cell population harboring
the BRAF V600E mutation in gangliogliomas [15].
In our study, BRAF V600E IHC interpretation was
usually straightforward with high (at least substantial)
interobserver agreement. The presence of rare cases with
nonspecific staining is a potential pitfall, which could
lead to rare false positive results. Similarly, others have also
reported negative cases with nonspecific background stain-
ing [15,32,34]. In ambiguous cases, sequential molecular
confirmatory testing is advocated [20,27]. We recommend
that pathologists not only be aware of the possibility of
nonspecific staining but also train during validation of the
IHC testing to correctly identify such cases and avoid mis-
interpretation of nonspecific staining as positive staining.
Conclusions
Detection of BRAF V600E mutation in PXA by immuno-
histochemistry is highly sensitive and specific with substan-
tial/almost perfect interobserver agreement. BRAF V600E
IHC interpretation is usually straightforward, but awareness
of possible nonspecific staining is necessary, and training
on the IHC stain interpretation is recommended. It is a
practical rapid method that may avoid the need of
labor-intensive molecular testing and may be extremely
valuable in biopsies unsuitable for molecular analysis
due to either small size or low tumor cell content.
Methods
Case selection
All studies were conducted according to Mayo Institutional
Review Board–approved protocols. This study was
approved by the Mayo IRB as a minimal risk study
with waiver of consent.
According to the Minnesota law, the Minnesota research
authorization status was reviewed and only patients whose
Research Status was "yes" were included in the study.
Fifty pleomorphic xanthoastrocytoma (PXA) cases upon
first surgical resection were selected from the files from
Mayo Clinic (n = 32) and Johns Hopkins University (n = 18)
from 1965 to 2011. All existing diagnostic slides were
retrieved and reviewed by at least two of the authors
(C.G. and C.M.I.), and the diagnosis of PXA was con-
firmed according to previously described criteria [23].
Tumors showed a relatively solid growth pattern and
were composed of a combination of spindle-shaped,
xanthic and pleomorphic, multinucleated giant astrocytes,
associated with both pale and bright eosinophilic granular
bodies. They included both classic PXA (≤5 mitotic figuresper 10 high power fields) and PXA with anaplastic features
(including >5 mitotic figures per 10 high power fields and/
or necrosis). All 50 cases were classified as either classic
PXA (n = 34) or PXA with anaplastic features (n = 16) and
were included in the study. Of these, 46 cases (92%) had
available tissue for IHC and/or molecular analysis.
BRAF V600E immunohistochemical analysis
Four-micron freshly cut sections (<2 weeks) of formalin-
fixed, paraffin-embedded (FFPE) tissue of 46 (of 50) cases
were dried and melting at 62°C oven for 20 minutes. Subse-
quently, they were stained with mouse monoclonal BRAF
V600E antibody (1/100 titer; clone VE1) and raised against
a synthetic peptide corresponding to amino acids 596–606
(GLATEKSRWSG) of mutant BRAF (Spring Bioscience)
with slight modifications to the manufacturer’s protocol.
Briefly, staining was performed on the Ventana BenchMark
XT (Ventana Medical Systems Inc.). The staining protocol
included online deparaffinization, HIER (Heat Induced
Epitope Retrieval) with Ventana Cell Conditioning 1
for 32 minutes and primary antibody incubation for
32 minutes at 37°C. Antigen-antibody reactions were
visualized using Ventana OptiViewTM Amplification
kit, followed by Ventana OptiViewTM Universal DAB
Detection Kit (Optiview HQ Linker 8 min, Optiview
HRP Multimer 8 min, Optiview Amplifier H2O2/
Amplifier 4 min, Optiview Amplifier Multimer 4 min,
Optiview H2O2/DAB 8 min, Optiview Copper 4 min).
Counterstaining was obtained online using Ventana
Hematoxylin II for 8 minutes followed by bluing reagent
for 4 minutes. Finally, all slides are removed from the
stainer, dehydrated, and coverslipped for microscopic exam-
ination. Positive control included a known BRAF V600E
mutant skin malignant melanoma. Cases were scored as
positive (“IHC-positive”), negative (“IHC-negative”), and
“negative-nonspecific” (“IHC negative/nonspecific”). Only
tumor cells showing non-ambiguous cytoplasmic staining
for BRAF V600E immunostain were scored as positive
(“IHC positive”). Faint, weak granular stain was noted in a
few cases and considered nonspecific. These cases were
scored as “IHC negative/nonspecific” for tracking purposes.
IHC slides were scored first by a primary reviewer and later
by three additional independent reviewers, all four blind to
the molecular results. The primary reviewer (CG) was the
one most intimately involved with the development of the
immunostain, who had gained most experience through
the process, and was most familiar with variations in stain
intensity and distribution not only among PXA cases but
also with other positive and negative controls. Because of
the level of expertise with reading the BRAF V600E
immunostain and of the sequence of events, the primary
reviewer was used as the “gold standard” to which the
results of the BRAF V600E mutation molecular analysis
were compared (see below). The four reviewers were
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BRAF V600E immunohistochemistry.
BRAF V600E mutation status by allele-specific PCR with
fragment analysis
After review of hematoxylin and eosin-stained slides, of
all the 50 cases, 37 (74%) cases had sufficient (≥20%) viable
tumor for BRAF V600E mutation molecular analysis. DNA
was extracted from 5-micron sections of FFPE tissue
(four to eight slides per case) using the QIAamp DNA
FFPE Tissue Kit (Qiagen) according to the manufacturer's
instructions with few modifications (samples were lysed
overnight; 10 uL of additional proteinase K was used on
the following day; the tissue was allowed to complete lysis
for additional one to two hours). DNA was quantified
using a Qubit fluorometer and Qubit Quant-iT dsDNA
BR Assay Kit (Invitrogen). Testing for the BRAF V600E
mutation was performed following clinically validated
protocols. BRAF allele-specific fluorescent PCR was
performed with primers specifically designed to detect
the base mutant and wild type base at position c.1799,
and fragment analysis was completed on the ABI 3730
DNA Analyzer (Applied Biosystems). The primers were dif-
ferentially labeled and had a size variance in addition to the
different fluorophore. Wild-type peak was approximately
155.2 base pairs, and the mutant peak was approximately
158 base pairs (predetermined bins were set at +/− 1.2 base
pairs from the expected size, i.e. 155.2 +/−1.2 bp and
158 +/−1.2 bp).
Statistical analysis
Sensitivity and specificity along with 95% confidence
intervals (score method) were calculated for BRAF V600E
IHC analysis based on the reading of the primary reviewer
compared to the BRAF V600E mutation molecular analysis
result considered the “gold standard”.
To evaluate the degree of agreement for IHC interpret-
ation among the four observers, overall kappa for >2
reviewers were calculated. Kappa values may vary from 0 to
1.0. Values of 0.4 to 0.6 are considered evidence of
“moderate” agreement, >0.6-0.8 of “substantial,” and >0.8-1
of “almost perfect” agreement according to Landis and
Koch [36]. Kappa was calculated based on the IHC scoring
results in two scenarios: when cases were scored as
“positive/negative” and when negative/nonspecific staining
was also taken into account [36-39]. All analyses were
performed using SAS version 9 (Cary, NC).
Additional files
Additional file 1: Figure S1. Fragment analysis electropherograms of a
BRAF V600E mutant case (case 14): mutant BRAF V600E peak in addition
to the wild- type BRAF peak, consistent with presence of BRAF V600E
mutation (A); positive control- mutant BRAF V600E peak in addition to thewild-type BRAF peak, consistent with presence of BRAF V600E mutation
(B); negative control- BRAF wild-type peak without mutant BRAF V600E peak,
consistent absence of BRAF V600E mutation (C); Blank/No DNA- Absence of
distinct peaks, indicating no sample contamination (D).
Additional file 2: Figure S2. Fragment analysis electropherograms of a
BRAF V600E non-mutant case (case 20): BRAF wild-type peak without
mutant BRAF V600E peak, consistent with absence of BRAF V600E
mutation (A); positive control- mutant BRAF V600E peak in addition to the
wild-type BRAF peak, consistent with presence of BRAF V600E mutation
(B); negative control- BRAF wild-type peak without mutant BRAF V600E
peak, consistent absence of BRAF V600E mutation (C); Blank/No DNA- Absence
of distinct peaks, indicating no sample contamination (D).
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